SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial - Concepedia

Concepedia

Publication | Closed Access

SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial

34

Citations

47

References

2023

Year

George Karavalakis, Efthymia Papadopoulou, Aliki Xochelli, Zoi Bousiou, Anastasios Vogiatzoglou, Penelope‐Georgia Papayanni, Aphrodite Georgakopoulou, Maria Giannaki, Fani Stavridou, Ioanna Vallianou,

Nature Medicine

Covid-19 PandemicImmunologySevere Covid-19Antiviral TherapyCovid-19 EpidemiologyRandomized Phase 1/2ImmunotherapyMedicineCovid-19

References

	Year	Citations

Page 1

Page 1